Business Standard

Monday, December 23, 2024 | 02:42 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Covishield third jab works against Omicron variant, says Oxford

If the vaccine is recommended for use as a booster against Omicron, it may significantly boost the demand for Covishield in India

vaccination
Premium

An Indian expert group on vaccination policy is yet to take a call on whether and when to allow Covid booster shots

Sohini Das Mumbai
A third booster shot of the AstraZeneca-Oxford Covid-19 vaccine Vaxzevria significantly boosts antibody levels against the Omicron variant of the coronavirus, claimed the British drug major.

This brightens the scope for Serum Institute of India (SII), which makes Covishield, the Indian version of the Vaxzevria. Experts are of the opinion that mixing vaccine shots may give better results to boost immunity. However, the University of Oxford has supported the use of Vaxzevria as a third booster dose against Omicron. SII is sitting on 500 million doses of Covishield (half of which is in bulk drug form), and has cut production

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in